12:00 AM
 | 
Feb 10, 2014
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/7 cls
Fluidigm Corp. (NASDAQ:FLDM) Cowen Doug Schenkel Downgrade Market perform (from outperform) -4% $43.11
Schenkel raised his target to $45 from $42, saying the company's single-cell genomics technologies and 2014 outlook are captured in the stock's price. Fluidigm reported 2013 revenues of $71.2M and expects a 23-28% increase in 2014. Schenkel is "increasingly weary" of the company's increased concentration in sample preparation vs. the higher revenue-generating analytical tools base. Fluidigm is acquiring DVS Sciences Inc., which develops and markets single-cell protein analysis systems, for about $207.5M in a cash and stock deal (see BioCentury, Feb. 3).
Gilead Sciences Inc. (NASDAQ:GILD) Baird Brian Skorney Upgrade Outperform (from neutral) -2%...

Read the full 799 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >